Production, validation, and commercialization of MagniLium (hyperpolarized helium

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$172,520.00
Award Year:
2007
Program:
SBIR
Phase:
Phase I
Contract:
1R43EB007439-01
Award Id:
85607
Agency Tracking Number:
EB007439
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
XEMED, LLC, 16 Strafford Avenue, DURHAM, NH, 03824
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
152959891
Principal Investigator:
JAN DISTELBRINK
(603) 868-1888
JAND@PHYSICS.UNH.EDU
Business Contact:
WILLIAM HERSMAN
() -
hersman@xemed.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Hyperpolarized gas MRI offers unprecedented pulmonary functional diagnostic capability. Pharmaceutical companies require sensitive diagnostic end points to determine the efficacy of COPD therapies they have under devel opment and accelerate their progress through FDA approval and into the marketplace. Individual sufferers of COPD could benefit from improved diagnosis and treatment. The US healthcare budget could benefit if the 35B spent on the 30 million Americans suffe ring from COPD could be directed towards effective treatments through accurate assessments. The primary obstacle to progress has been the availability of high quality hyperpolarization technology and services for both technical and legal reasons. We see a clear path to overcoming those obstacles. We propose to assemble a world-leading 3He polarizer using the low-cost spin-exchange optical pumping technique. New optical pumping technologies, many developed by us only recently and others to be developed in th is proposal, will allow production of 55% polarization at 100 bar-liters per day and as high as 70% polarization at one-third that rate. This phase of the project includes submission of the product gas as an Investigational New Drug (IND) to the US FDA. A subsequent phase will include refinement and duplication of the prototype, utilization of the prototype to partner with clinical and pharmaceutical research centers for human trials, and submission of a New Drug Application (NDA) to the FDA. FDA safe harbo r laws protect drug development as a non-infringing activity.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government